2025年12月4日，科伦博泰与Crescent Biopharma达成了一项总金额超 13 亿美元的战略合作。根据协议，Crescent获得科伦博泰 ITGB6 ADC（SKB105）的大中华区以外全球权益，为此支付 8000 万美元首付款及最高 12.5 亿美元的里程碑金额；作为交换，科伦博泰反向引进 Crescent的PD-1/VEGF双抗（CR-001），获得其在大中华区的独家权益，并支付...
Source Link2025年12月4日，科伦博泰与Crescent Biopharma达成了一项总金额超 13 亿美元的战略合作。根据协议，Crescent获得科伦博泰 ITGB6 ADC（SKB105）的大中华区以外全球权益，为此支付 8000 万美元首付款及最高 12.5 亿美元的里程碑金额；作为交换，科伦博泰反向引进 Crescent的PD-1/VEGF双抗（CR-001），获得其在大中华区的独家权益，并支付...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.